替拉珠单抗免疫原性对药代动力学、疗效和安全性的影响评估
基于三项临床试验(P05495、reSURFACE 1和reSURFACE 2)的慢性斑块状银屑病患者数据,评估替拉珠单抗的免疫原性。未观察到抗药抗体与安全性事件之间的明确关联。
要点
- 替拉珠单抗长期治疗中抗药抗体发生率低,约3%患者出现治疗中出现的中和抗体。
- 未观察到抗药抗体与潜在免疫原性相关不良事件之间的明确趋势。
核心结论
- 替拉珠单抗治疗52-64周时抗药抗体发生率低,约3%患者出现治疗中出现的中和抗体,并显示血清浓度降低和疗效相应下降。
- 未观察到抗药抗体与安全性之间的关系。
研究设计与样本
- 基于三项临床试验(P05495、reSURFACE 1和reSURFACE 2)的慢性斑块状银屑病患者数据。
- 在1400例(第12-16周)和780例(第52-64周)随机接受替拉珠单抗100 mg或200 mg的可评估患者中,识别治疗中出现抗药抗体阳性患者并表征中和抗体。
- 按抗药抗体状态评估药代动力学、安全性和疗效。
主要发现
- 持续接受替拉珠单抗100 mg或200 mg治疗的患者中,第52-64周时<7%为不确定结果。
- 持续治疗至第52周时,TE-POS NAb-POS与ADA阴性患者的PASI改善率:100 mg组为76%(n=10)vs. 91%(n=342);200 mg组为77%(n=12)vs. 87%(n=299)。
- 至第52-64周,任何ADA阳性患者类别与ADA阴性患者相比,潜在免疫原性相关不良事件发生率未显示明确趋势。
关键数值与推荐
- 持续治疗至第52周PASI改善率:100 mg组TE-POS NAb-POS 76%(n=10)vs. ADA阴性91%(n=342);200 mg组77%(n=12)vs. 87%(n=299)。
临床怎么用
- 替拉珠单抗治疗中抗药抗体发生率低,但出现治疗中出现中和抗体的患者可能血清浓度降低且疗效减弱。
- 抗药抗体状态与安全性事件无明确关联,临床无需仅因抗药抗体阳性而常规调整安全性监测。
局限性
- TE-POS NAb-POS患者样本量较小(100 mg组n=10,200 mg组n=12),疗效比较需谨慎解读。
- 第12-16周抗药抗体对药代动力学、疗效和安全性影响的数据仅以汇总形式提及,未在摘要中详细报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We evaluated antidrug antibody (ADA) development in patients with chronic plaque psoriasis from three clinical trials of tildrakizumab, a humanized anti-interleukin-23p19 monoclonal antibody (P05495, reSURFACE 1 and reSURFACE 2). OBJECTIVES: To determine the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab. METHODS: In 1400 (weeks 12-16) and 780 (weeks 52-64) evaluable patients randomized to tildrakizumab 100 or 200 mg, treatment-emergent ADA-positive (TE-POS) patients were identified and characterized for neutralizing antibodies (NAbs). Pharmacokinetics, safety and efficacy were evaluated by ADA status. RESULTS: In patients treated with tildrakizumab 100 or 200 mg continuously, < 7% were inconclusive at 52-64 weeks. In long-term data through 52-64 weeks, the incidence of TE-POS was 6·5% (100 mg) and 8·2% (200 mg) and the incidence of TE-POS NAb-POS was 2·5% (100 mg) and 3·2% (200 mg). TE-POS NAb-POS patients had modestly increased median tildrakizumab clearance (36·5%) compared with ADA-NEG patients. Percentage Psoriasis Area and Severity Index improvements in TE-POS NAb-POS vs. ADA-NEG patients on continuous treatment through week 52 were 76% (n = 10) vs. 91% (n = 342) for 100 mg and 77% (n = 12) vs. 87% (n = 299) for 200 mg. The incidence of potential immunogenicity-related adverse events did not indicate a clear trend in any positive ADA patient category compared with ADA-NEG patients through weeks 52-64. The effects of ADA on pharmacokinetics, efficacy and safety at 12-16 weeks were also summarized. CONCLUSIONS: ADA development with tildrakizumab treatment for 52-64 weeks was low; around 3% of patients developed TE-POS NAb-POS ADAs and showed lower serum concentrations and corresponding reduced efficacy. No relationship between ADAs and safety was observed. What's already known about this topic? Unwanted immune responses - for example immunogenicity and antidrug antibodies (ADAs) - have been observed with therapeutic monoclonal antibodies and can affect efficacy and safety. Tildrakizumab is a humanized monoclonal antibody targeting interleukin-23 and is currently approved for patients with plaque psoriasis. What does this study add? ADA development in tildrakizumab-treated patients with psoriasis over 52 weeks was low. The small proportion of patients who had treatment-emergent ADAs and had neutralizing antibodies experienced lower serum tildrakizumab concentrations and reduced efficacy. No relationship between ADAs and safety events was observed.
引用
- Kimball AB, Kerbusch T, van Aarle F, et al. Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab. Br J Dermatol. 2019. PMID: 30916381. doi:10.1111/bjd.17918
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。